SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-----------
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT
TO RULE 13d-2(a)
(Amendment No. 7)
Thoratec Corporation
(Name of Issuer)
Common Stock, no par value per share
(Title of Class of Securities)
885175 30 7
(CUSIP Number)
Seth H. Hoogasian, Esq.
General Counsel
Thermo Electron Corporation
81 Wyman Street
Waltham, Massachusetts 02454-9046
(781) 622-1000
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
April 27, 2005
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box ?.
Note. Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See Rule 13d-7(b)
for other parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 6 Pages)
------------------------------ -------------------------------------
CUSIP NO. 885175 30 7 13D Page 2 of 6 Pages
------------------------------ -------------------------------------
-------- -----------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Thermo Electron Corporation
04-2209186
-------- -----------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
-------- -----------------------------------------------------------------------
3. SEC USE ONLY
-------- -----------------------------------------------------------------------
4. SOURCE OF FUNDS*
SC
-------- -----------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(d) or 2(e) [ ]
-------- -----------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware
---------------------------- -------- ------------------------------------------
NUMBER OF SHARES 7. SOLE VOTING POWER
BENEFICIALLY OWNED BY EACH 238,000
REPORTING PERSON WITH
-------- ------------------------------------------
8. SHARED VOTING POWER
-0-
-------- ------------------------------------------
9. SOLE DISPOSITIVE POWER
238,000
-------- ------------------------------------------
10. SHARED DISPOSITIVE POWER
-0-
---------------------------- -------- ------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
238,000
---------- ---------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
---------- ---------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
.5%
---------- ---------------------------------------------------------------------
14. TYPE OF REPORTING PERSON*
CO
---------- ---------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Thermo Electron Corporation, a Delaware corporation (the "Reporting
Person"), hereby amends its statement on Schedule 13D relating to the common
stock, no par value per share (the "Common Stock"), of Thoratec Corporation
(formerly known as Thoratec Laboratories Corporation), a California corporation
(the "Company").
ITEM 2. Identity and Background.
Item 2 is hereby amended and restated as follows:
This Amendment is being filed by the Reporting Person pursuant to Rule
13d-2 to reflect the change of information previously reported under Item 5 of
its Schedule 13D, as amended.
The principal business address and principal office address of the
Reporting Person is 81 Wyman Street, Waltham, Massachusetts 02454-9046.
The Reporting Person is a leading provider of analytical and monitoring
instruments used in a broad range of applications, from life sciences research
to telecommunications to food, drug, and beverage production.
Appendix A attached to hereto sets forth with respect to each executive
officer and director of the reporting Person the following information:
(a) name;
(b) business address;
(c) present principal occupation or employment and the name,
principal business and address of any corporation or other
organization in which such employment is conducted; and
(d) citizenship.
To the knowledge of the Reporting Person, there is no person who may be deemed
to be a controlling person of the Reporting Person.
During the last five years, neither the Reporting Person nor, to the
knowledge of the Reporting Person, any executive officer or director of the
Reporting Person has been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors).
During the last five years, neither the Reporting Person nor, to the
knowledge of the Reporting Person, any executive officer or director of the
Reporting Person has been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction which resulted in a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, Federal or State securities laws or finding any
violation with respect to such laws.
ITEM 5. Interest in Securities of the Issuer.
Item 5 is hereby amended and restated in its entirety as follows:
(a) As of the date of this Amendment, the Reporting Person owns 238,000
shares of Common Stock which represents .5% of the outstanding Common Stock of
the Company, based
(Page 3 of 6)
upon the total Common Stock outstanding as reported on the Company's Form 10-K/A
for the fiscal year ended January 1, 2005. Information with respect to the
beneficial ownership of the shares of Common Stock of the other persons named in
Item 2 is set forth in Appendix A. Except as set forth in this Item 5, to the
best knowledge of the Reporting Person, none of the parties named in Item 2 owns
any of the Company's Common Stock.
(b) As a result of the Reporting Person's ownership having been reduced to
below 5% of the Company's outstanding shares of Common Stock and pursuant to the
terms of the Shareholder Agreement, the Reporting Person has the sole power to
vote all 238,000 shares beneficially owned by it. Subject to the terms of the
Shareholder Agreement, the Reporting Person has the sole power to dispose of the
shares of Common Stock beneficially owned by it. With respect to the shares of
Common Stock of the Company beneficially owned by the other persons named in
Item 2, except as set forth in Appendix A, each such person has the sole power
to vote all of such shares and the sole power to dispose of all of such shares.
Item 1 sets forth the Company's name and state of incorporation along with
the address of its principal business and principal office. The Company's
principal business is the research, development, manufacturing and marketing of
medical devices for circulatory support and vascular graft applications. To the
best knowledge of the Reporting Person, during the last five years, the Company
(i) has not been convicted in any criminal proceeding (excluding traffic
violations or similar misdemeanors) and (ii) was not a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction as
result of which it was or is subject to a judgment, decree or final order
enjoining future violations of, or prohibiting or mandating activities subject
to, Federal or State securities laws or finding any violation with respect to
such laws.
(c) Except as described below in this Item 5 and in Item 4, which item is
incorporated herein by reference, neither the Reporting Person nor, to the
knowledge of the Reporting Person, any person named in Appendix A beneficially
has effected any transactions in Common Stock during the past 60 days.
The Reporting Person has affected the following open market sales with
respect to the Common Stock since the filing of Amendment No. 6 to its Schedule
13D:
---------------------- ------------------------------ --------------------------
Date Amount Price Per Share
---------------------- ------------------------------ --------------------------
4/14/05 35,000 $12.36
---------------------- ------------------------------ --------------------------
4/15/05 5,500 $12.34
---------------------- ------------------------------ --------------------------
4/19/05 68,000 $12.07
---------------------- ------------------------------ --------------------------
4/20/05 39,600 $11.95
---------------------- ------------------------------ --------------------------
4/21/05 57,444 $11.93
---------------------- ------------------------------ --------------------------
4/22/05 100,000 $11.81
---------------------- ------------------------------ --------------------------
4/26/05 70,000 $11.63
---------------------- ------------------------------ --------------------------
4/27/05 1,520,000 $13.02
---------------------- ------------------------------ --------------------------
4/28/05 460,000 $13.29
----------------------- ------------------------------ -------------------------
(Page 4 of 6)
4/29/05 375,000 $13.00
----------------------- ------------------------------ -------------------------
5/2/05 371,200 $12.96
---------------------- ------------------------------ --------------------------
5/3/05 163,800 $13.00
---------------------- ------------------------------ --------------------------
5/4/05 500,000 $13.19
---------------------- ------------------------------ --------------------------
5/5/05 178,100 $13.79
---------------------- ------------------------------ --------------------------
5/6/05 111,900 $13.89
---------------------- ------------------------------ --------------------------
5/9/05 142,000 $13.59
---------------------- ------------------------------ --------------------------
(d) None.
(e) April 28, 2005
(Page 5 of 6)
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: May 11, 2005
THERMO ELECTRON CORPORATION
By: /s/ Peter M. Wilver
---------------------------
Name: Peter M. Wilver
Title: Vice President and Chief
Financial Officer
(Page 6 of 6)
APPENDIX A
Thermo Electron Corporation
The name, present principal occupation or employment and beneficial
ownership of shares of common stock of Thoratec Corporation (the "Company") of
each director and executive officer of Thermo Electron Corporation ("Thermo
Electron") is set forth below. Unless otherwise noted, all such individuals are
citizens of the United States. Unless otherwise noted, the business address of
each executive officer and director of Thermo Electron is 81 Wyman Street,
Waltham, Massachusetts 02454-9046.
Directors
-------------------------------------- ---------------------------------------- ---------------------------------------------
Beneficial Ownership of Shares of the
Company Common Stock
------------- ----------------- -------------
Shares
Underlying
Options
Exercisable Total
Name/Present Principal Shares Held Prior to April Beneficial
Occupation or Employment Business Address Outright 27, 2005 Ownership
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
John L. LaMattina Pfizer Inc. 0 0 0
Senior Vice President of Pfizer Inc. 50 Pequot Avenue
and the President of Pfizer Global New London, Connecticut 06230
Research and Development
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Peter J. Manning
Director of Safety Insurance Group 0 0 0
Inc.
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Jim P. Manzi
Chairman of the Board of Thermo
Electron and Chairman of Stonegate 0 0 0
Capital
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Robert A. McCabe 4,393 0 4,393
Chairman of Pilot Capital Corporation
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Robert W. O'Leary Valeant Pharmaceuticals International 0 0 0
Chairman of Valeant Pharmaceuticals 3300 Hyland Avenue
International Costa Mesa, California 92626
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Michael E. Porter Harvard Business School 0 0 0
Bishop William Lawrence Soldiers Field Road
University Professor at Boston, Massachusetts 02163
Harvard Business School
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Elaine S. Ullian Boston Medical Center 0 0 0
President and Chief Executive Talbot 1
Officer of Boston Medical Center One Boston Medical Center Place
Boston, Massachusetts 02118
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Marijn E. Dekkers(1) 0 0 0
President, Chief Executive Officer
and Director of Thermo Electron
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
(1) Mr. Dekkers is a citizen of The Netherlands.
(Page A - 1)
Executive Officers Who are Not Directors
No person is a controlling stockholder of Thermo Electron.
-------------------------------------- ---------------------------------------- ---------------------------------------------
Beneficial Ownership of Shares of the
Company Common Stock
------------- ----------------- -------------
Shares
Underlying
Options
Exercisable Total
Name/Present Principal Shares Held Prior to April Beneficial
Occupation or Employment Business Address Outright 27, 2005 Ownership
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Guy Broadbent(2) 0 0 0
Vice President of Thermo Electron
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Marc N. Casper 0 0 0
Senior Vice President of
Thermo Electron
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Seth H. Hoogasian 0 0 0
Vice President, General Counsel and
Secretary of Thermo Electron
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Peter E. Hornstra 0 0 0
Corporate Controller and Chief
Accounting Officer of Thermo Electron
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Stephen G. Sheehan 0 0 0
Vice President, Human Resources of
Thermo Electron
-------------------------------------- ---------------------------------------- ------------- ----------------- -------------
Peter M. Wilver 0 0 0
Vice President and Chief Financial
Officer of Thermo Electron
------------------------------------------------------------------------------- ------------- ----------------- -------------
All directors and current executive officers as a group 4,393 0 4,393
------------------------------------------------------------------------------- ------------- ----------------- -------------
(2) Mr. Broadbent is a citizen of the United Kingdom.
(Page A - 2)